Bo Ahrén
41 – 50 of 393
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Albiglutide for the treatment of type 2 diabetes mellitus : An integrated safety analysis of the HARMONY phase 3 trials
(
- Contribution to journal › Article
-
Mark
The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
(
- Contribution to journal › Article
-
Mark
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus : Long-term efficacy with or without rescue therapy
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide : effects alone and in combination on insulin secretion and glucose disappearance in mice
(
- Contribution to journal › Article
-
Mark
High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes : A randomized clinical trial
(
- Contribution to journal › Article
-
Mark
Alain Ktorza, PhD
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
Mixed meal diminishes glucose excursion compared to glucose by several adaptive mechanisms in man.
(
- Contribution to journal › Article
-
Mark
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
(
- Contribution to journal › Article
-
Mark
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
2016) In Diabetologia(
- Contribution to journal › Article